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Advances in the treatment of patients with pancreatic
cancer: improvement in symptoms and survival time
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Summary Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes
pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside
analogue gemcitabine (GEMZAR®) has been shown to provide clinical benefit for patients (decreased pain and improved performance status)
as well as to improve the time to tumour progression and survival for patients with the disease. There are also other new agents that are
presented in this discussion, such as the multi-targeted antifolate MTA, capecitabine and the ONYX-015 adenovirus, which replicates in, and
kills, only p53-abnormal cells, which have the potential to have an impact on this terrible disease.
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Pancreatic cancer kills more than 28 000 patients each year in the
USA (Parker et al, 1997) and almost 7 000 patients each year in
the UK (Black et al, 1997). It is the fourth leading cause ofdeath in
the USA and the sixth most common cause ofdeath from cancer in
men and women in the UK. Unfortunately, most patients with
pancreatic cancer present with advanced disease. Therefore, the 5-
year survival for patients with advanced pancreatic cancer is the
lowest of any tumour type covered by the SEER database, with
2-5% ofpatients alive at 5 years.
The standard treatment for patients with advanced pancreatic
cancer has been 5-fluorouracil (5-FU). The response rate for this
single agent has ranged from 0% to 43% (Moore, 1994). Although
there have been quite significant efforts in trying to find new treat-
ments for patients with advanced pancreatic cancer; there have,
unfortunately, been no agents or combinations of agents that have
demonstrated a response rate of > 20%. This has recently been
reviewed by Moore (1994). A myriad ofcombination regimens have
been assembled and tested (Frey et al, 1981; Horton et al, 1981;
Bukowski et al, 1983; Cullinan et al, 1985, 1991; GITSG, 1986;
Oster et al, 1986; Kelsen et al, 1991; Moore, 1994). Once again,
there is no evidence from these studies that combination chemo-
therapy is superior to therapy with 5-FU. The median survival of
patients receiving single-agent 5-FU or 5-FU in combination with
agents such as doxorubicin, mitomycin C, cisplatin, streptozotocin
or others, is 4 months (range 1.8-10 months) (Frey et al, 1981;
Horton et al, 1981; Bukowski et al, 1983; Cullinan et al, 1985, 1990;
GITSG, 1986; Oster et al, 1986; Kelsen et al, 1991; Moore, 1994).
Because of the disappointing results with both single agents and
combinations for treatment of patients with advanced disease, there
has even been reluctance to study new agents and combinations in
patients with pancreatic cancer (Wils, 1991; Taylor, 1993), although
not everyone has felt that way (Casper, 1993, Moore, 1994).
Correspondence to: DD Von Hoff
THE AGENT: GEMCITABINE
Gemcitabine (dFdC, 2'-2'-difluorodeoxycytidine, GEMZAR®,
LY188011) (Figure 1) is a novel nucleoside that has significant
anti-tumour activity in vitro and in vivo (Heinemann et al, 1988;
Hertel et al, 1990; Huang et al, 1991). Table 1 lists the tumour
types against which gemcitabine has in vivo activity.
Mechanism of action
Gemcitabine requires intracellular phosphorylation, which results
in the accumulation of difluorodeoxycytidine triphosphate
(dFdCTP) (Heinemann et al, 1988). Gemcitabine inhibits DNA
synthesis as dFdCTP competes with dCTP for incorporation into
DNA (Heinemann et al, 1988; Huang et al, 1991). Gemcitabine
also reduces intracellular deoxynucleoside triphosphate pools, an
effect that is felt to be secondary to the agent's inhibition of
ribonucleotide reductase (Ghandi and Plunkett, 1990).
With the discovery of gemcitabine and its entry into phase I
clinical trials, the San Antonio team began studying the activity of
gemcitabine in a human tumour cloning assay (Hanauske et al,
1992; Von Hoff, 1996). This was carried out to help select the most
appropriate schedule for phase I trials, to predict target plasma
concentrations that must be achieved to have anti-tumour activity
and to select the tumour types against which the new agent should
be targeted in future phase II studies. Using both growth ofhuman
tumour colony-forming units in capillary tubes (Hanauske et al,
1992) and in Petri dishes (Von Hoff, 1996), gemcitabine demon-
strated a very broad spectrum of anti-tumour activity with a
concentration-response effect against non-small-cell lung, breast,
ovarian and pancreatic cancer colony-forming units. Based on
these results, gemcitabine was predicted to have a broad spectrum
of anti-tumour activity; a prediction subsequently borne out in
follow-up clinical trials. What was particularly striking to us,
however, was the activity ofgemcitabine against pancreatic cancer
tumour colony-forming units. Before this, we had seen virtually no
activity for over 100 new agents against this disease, and this new
information encouraged our group to enter patients with pancreatic
cancer on the phase I study.
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Figure 1 Structure of gemcitabine
Table 1 Tumour types against which gemcitabine has activity
X 5563 myeloma
Adenocarcinoma 755
6C3HED lymphosarcoma
M-5 ovarian
L-1210 leukaemia
P388 leukaemia
p 1534J leukaemia
Friend's leukaemia
LX-1 xenograft
CX-1 xenograft
PANC 02
MIAPaCa
PANC 03
(Heinemann et al, 1988; Hertel et al, 1990; Huang et al, 1991)
Initial phase I clinical trial with gemcitabine
Two different phase I trial schedules were examined in San
Antonio, including administration daily x 5 (O'Rourke et al, 1994)
and every 2 weeks (Brown et al, 1991). The daily x 5 schedule was
extremely toxic with dose-limiting toxicities of hypertension,
fever and flu-like symptoms seen at a dose of only 9 mg m-2. Of
note was that on the every 2 weeks schedule, the maximum-toler-
ated dose was 400-fold higher (3600 mg m-2). The dose-limiting
toxicities included a rash, seen in one female patient, and other
systemic, flu-like symptoms. The fact that one patient with pancre-
atic cancer on the every 2 week schedule had improvement of her
symptoms, plus the in vitro and in vivo activity of gemcitabine
against pancreatic cancer, led to the initial phase II trials with
gemcitabine for patients with pancreatic cancer.
Initial phase 11 trial with gemcitabine in patients with
advanced pancreatic cancer
The initial phase II trial of gemcitabine in patients with advanced
pancreatic cancer was conducted by Casper and colleagues with
doses of800-1250 mg m-2 i.v. weekly x 3 every 28 days (Casper et
al, 1994). Forty-three patients were entered on study, none ofwhom
had received prior chemotherapy. Toxicities with the regimen were
mild. There were five partial responses in 39 evaluable patients,
giving a 13% response rate. Responses were 13, 4 +, 17, 8 and 20 +
months in duration. However, even though the overall response rate
was low, there were two things that impressed the clinicians caring
for these patients: patients with long-term survival and patients
who had improvement in their pain (Casper et al, 1994). These
observations led to the consideration that perhaps gemcitabine was
an agent that had an anti-tumour effect greater than that that could
be measured by the area ofthe tumour.
PANCREATIC CANCER PATIENTS ARE SPECIAL
Most patients with pancreatic cancer have symptoms and signs
including pain, weight loss and a declining performance status.
Their disease is frequently difficult to measure because they may
have had prior surgery in the pancreas bed, prior radiotherapy to
the tumour bed or a pancreatitis/phlegmon associated with the
tumour. Therefore, it is possible that patients experiencing an
improvement in their pain after they received gemcitabine could
be having an anti-tumour effect without a measurable decrease in
the tumour size, over and above those patients who had clear-cut
partial responses.
The concept of clinical benefit
We proposed the concept ofclinical benefit as a way to objectively
measure whether or not gemcitabine was improving the symptoms
of patients with pancreatic cancer, including pain, decreased
performance status and weight loss.
Clinical benefit was a composite of measures previously used
by others to measure whether or not 5-FU or 5-FU plus other
agents improved performance status, weight and clinical symp-
toms of patients with pancreatic or gastric cancer (Cullinan et al,
1985). However, the strategy by which clinical benefit was
assessed in the gemcitabine studies used a more rigorous method
that built on the work ofCullinan. Andersen and colleagues (1994)
prospectively developed this method in which improvement of
pain, as assessed by the Memorial Pain Assessment Card (MPAC)
(Fishman et al, 1987) and by analgesic consumption and perfor-
mance status, had to be substantial and durable, and the patient's
weight had to improve by at least 7% (Andersen et al, 1994; Burris
et al, 1997).
The details of the rigour with which the clinical benefit instru-
ment was constructed are outlined in the recent publication by
Burnis and colleagues (Burris et al, 1997). Pain, assessed by pain
intensity and analgesic consumption recorded daily by the patient,
and functional improvement assessed by Karnofsky performance
status (KPS), were the primary measures of clinical benefit.
Weight change was considered a secondary measure and was
assessed weekly. A positive benefit for pain was recorded if there
was a significant (. 50%) improvement from baseline in both
pain intensity and analgesic consumption which was sustained for
.4 weeks.
A positive for performance status was an improvement of. 20
points from baseline sustained for 2 4 weeks. As noted above, a
positive clinical benefit for weight gain (excluding patients with
third-space fluid) was a weight gain of 2 7% from baseline,
sustained for 2 4 weeks (for further details see the paper by Burris
and colleagues, 1997).
This clinical benefit parameter was put in place and two addi-
tional phase II trials were performed.
Additional phase 11 trials of gemcitabine in patients with
pancreatic cancer
Rothenberg and colleagues (1996) reported on the activity of
gemcitabine (1000 mg m-2 weekly for 7 weeks followed by a week
of rest and then once weekly for 3 of 4 weeks) in patients with
5-FU-refractory pancreatic cancer. They noted that 17 of the 63
patients (27%) had improvement in their pain status or perfor-
mance status. Toxicities were mild to moderate, with 16 patients
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having grade 3-4 granulocytopenia, and six patients having a skin
rash. The authors concluded that patients receiving gemcitabine
did have clinical benefit. An accompanying editorial claimed that,
in the absence of a randomized clinical trial, 'the evidence of
substantial benefit from gemcitabine is certainly not over-
whelming' (Gelber, 1996).
Carmichael and colleagues (1995) treated patients with pancre-
atic cancer who had not had prior chemotherapy, with doses of
gemcitabine ranging from 820 to 1000 mg m-2 weekly for 3 out of
every 4 weeks. Thirty-four patients were entered on study. A
partial response was noted in 2 of 32 evaluable patients for an
overall response rate of 6.3%. Of additional interest was that 28%
of patients had improvement in their pain, 17% had improvement
in performance status and 27% had improvement in nausea. Fewer
than 10% of patients had grade 4 neutropenia or thrombo-
cytopenia. Grade 3 nausea and vomiting was noted in 27% of
patients. The median survival of the patients was 6.3 months
(Carmichael et al, 1995).
A DEFINITIVE PHASE III TRIAL OF
GEMCITABINE IN PATIENTS WITH ADVANCED
PANCREATIC CANCER
Based on the above interesting leads, a definitive clinical trial was
designed to determine whether or not gemcitabine could provide
clinical benefit for patients with advanced pancreatic cancer, as
well as improve response rates and survival. The design of the
randomized trial is shown in Figure 2. It is of note that this trial
was originally designed as a double-blinded trial. However,
because skin rash could be seen with each agent (and one would
treat through the gemcitabine-induced skin rash, but not through
the 5-FU-induced skin rash), the investigators felt that safety
demanded that the trial be only single-blinded, with only patients
not knowing which agent they were receiving.
The primary end point for this study was clinical benefit, which
has been outlined above. Other end points included in the study
were (a) time to tumour progression, (b) response rate, (c) median
survival and (d) 1-year survival.
The results of the randomized trial are outlined in Table 2
(Burris et al, 1997). There were 63 patients per arm. As can be
seen from the table, 23.8% ofthe gemcitabine-treated patients and
4.8% of those treated with 5-FU experienced clinical benefit
(P = 0.0022). It is of note that patients with a clinical benefit
response had a longer median survival (10.7 vs 4.8 months) than
patients who did not have a clinical benefit response. The median
Patients with advanced
symptomatic pancreatic
cancer
- No prior chemotherapy
- Measurable/evaluable
lesions outside field of
radiotherapy
- KPS 2 50 but < 80
-Analgesic consumption
> 10 morphine sulfate equivalents
- Pain intensity score of
.20 (out of 100) on MPAC
5-FU
(600 mg m-2 over 30 min
once weekly)
Gemcitabine
(1000 mg m-2 over 30 min
once weekly x7)
Figure 2 Design of randomized trial in patients with advanced pancreatic
cancer
Table 2 Results of randomized trial of gemcitabine vs 5-fluorouracil in
patients with advanced pancreatic cancer
Parameter 5-FU Gemcitabine P-value
Clinical benefit (%) 4.8 23.8 0.0022
Partial response (%) 0.0 5.4 0.077
Time to tumour progression (months) 1.0 3.2 0.0002
Survival
Median (months) 4.41 5.65 0.0025
1-year (%) 2.0 18.0
Table 3 Percentage of patients with grade 3-4 toxicities in each arm of the
gemcitabine vs FU study
Toxicity 5-FU (%) Gemcitabine(%)
Anaemia 0.0 9.7
Neutropenia 4.4 25.9a
Thrombocytopenia 1.6 9.7
Nausea and vomiting 4.8 12.7
Diarrhoea 4.8 1.6
Mucositis (grade 1-2) 14.8 14.3
Alopecia (grade 1-2) 0.0 0.0
a6.6% Grade 4.
survivals were 5.65 months for the gemcitabine-treated patients
and 4.41 months for the 5-FU-treated patients (P = 0.0025). There
was also a vigorous effect for the time to tumour progression
(P = 0.0002). Patients with a clinical benefit response had a longer
time until progressive disease (3.7 vs 1.6 months) than patients
who did not have a clinical benefit response. Of additional note is
that the survival at 12 months for gemcitabine patients was 18%,
while the survival at 12 months was 2% for the 5-FU patients. The
percentage ofpatients with grade 3-4 toxicities in each arm ofthe
study is outlined in Table 3.
Gemcitabine is the first new agent ever to have an impact on the
symptoms that affect patients with advanced symptomatic pancre-
atic cancer, and to have an impact on the time to tumour progres-
sion and the survival of patients with advanced, symptomatic
pancreatic cancer. Furthermore, this effect ofgemcitabine is noted
with very tolerable side-effects.
FUTURE DIRECTIONS FOR TREATMENT OF
PATIENTS WITH PANCREATIC CANCER
Gemcitabine
Gemcitabine will undoubtedly be placed in combination with other
agents to treat patients with pancreatic cancer. There is increasing
evidence that the combination of a differentiating agent plus gem-
citabine has activity in preclinical models ofpancreatic cancer that
is superior to the activity of gemcitabine alone (Wick et al, 1997).
This finding should be investigated in the clinical setting.
MTA
MTA (LY231514), a novel multi-targeted antifolate antimetabolite,
is ahighlyinteresting agentthathas abroad spectrumofanti-tumour
activity. Our team in San Antonio has already noted responses in
patients with pancreatic cancer (Rinaldi et al, 1995, 1996).
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Capecitabine
This agent, which is given orally, also has promising activity in
patients with gastrointestinal malignancies (Twelves et al, 1996;
Findlay et al, 1997).
Other agents
Other promising agents include the farnesyl transferase inhibitors
that have not yet entered clinical trials. These inhibitors should
inhibit the growth of ras-abnormal pancreatic cancer cells.
The other agent that is of interest is the adenovirus ONYX-015,
which replicates only in p53-abnormal cells (Ganly et al, 1997;
Heise et al, 1997). About 60% of pancreatic cancer specimens
have abnormalities in p53 by immunohistochemistry (Barton et al,
1991). Clinical trials with ONYX-015 given by direct injection
into the pancreatic cancer have already begun.
SUMMARY
There are some new treatments available for patients with
advanced pancreatic cancer. Gemcitabine is the first new agent
that has been found to have a positive effect on clinical benefit
(pain and performance status) for patients and to improve their
survival. There are also promising new agents, such as MTA,
capecitabine and ONYX-015, which are also likely to have an
impact on this disease.
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